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ABSTRACT 
 
Background 
Cancer patients have elevated risk of both stroke and bleeding in comparison to individuals 
without cancer. The general population is ageing and the group of patients with atrial 
fibrillation (AF) and cancer concomitantly becomes larger; however, there is lack of stroke 
prevention guidelines addressing these patients. The aim of this thesis was to describe stroke 
prevention with oral anticoagulants (OACs) in AF patients with cancer and to estimate net 
benefit. 
 
Methods and Results 
Register data on all patients with at least one registered diagnosis of AF in the Swedish 
Patient Register between 1 July 2005 and 31 December 2017 were cross-matched with the 
Drug Register, the Cancer Register, the Cause of Death Register, and the Riksstroke Register. 
Patients with a new cancer diagnosis within the past year and patients without a cancer 
diagnosis in the last five years were included. 
 
Study I: Propensity score matching for the likelihood of being on OAC treatment after having 
been diagnosed with AF was used to study patients with and without OAC treatment. Cancer 
(n=14,472) and non-cancer (n=304,286) patients were analysed separately. Amongst cancer 
patients, there was an overall net benefit of OAC use for the composite outcome of ischaemic 
stroke, extracranial arterial thromboembolism, bleedings, and death (hazard ratio [HR]: 0.81, 
95% confidence interval [CI]: 0.78–0.85). This result is driven by patients with at least 
intermediately increased stroke risk. Limiting follow-up to one year and accounting for the 
competing risk of death, there was a net cerebrovascular benefit for OACs generally 
(subhazard ratio [sHR]: 0.67, CI: 0.55–0.83) and for non-vitamin K antagonist OACs 
(NOACs) (sHR: 0.65, CI: 0.48–0.88) over warfarin. 
 
Study II: In Riksstroke we identified all AF patients who had suffered an ischaemic stroke. 
Amongst cancer patients (n=1,518) the proportion prescribed OACs at discharge increased by 
40.2% after NOACs were introduced, compared with 69.3% in non-cancer patients 
(n=50,953), even though stroke and bleeding risk scores remained similar between the patient 
groups. OAC dispensation during the following year increased less in cancer patients (43.8% 
to 64.5%) than in non-cancer patients (46.0% to 74.9%), and the median time to OAC 
dispensation was significantly longer (94 vs. 30 days) after the introduction of NOACs. 
 
Study III: There was no difference in net cerebrovascular benefit amongst patients with 
cancer (n=8,228) and without cancer (n=323,394) during the year following OAC initiation 
adjacent to AF diagnosis accounting for the competing risk of death (sHR: 1.12, CI: 0.98–
  
1.29). Cancer patients had a higher risk of non-fatal bleedings (sHR: 1.69, CI: 1.56–1.82). 
NOACs were associated with lower risk of both cerebrovascular events and bleedings 
compared to warfarin. Amongst NOAC treated, cancer was not a predictor of intracranial 
bleedings. 
 
Conclusions 
AF patients with cancer have a net benefit from OAC treatment and may be treated according 
to current AF guidelines for the general AF population, but they should be monitored closely 
for bleedings. NOACs appear safer than warfarin, but seem underutilised as secondary 
prevention after ischaemic stroke amongst cancer patients. 
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LIST OF ABBREVIATIONS 
 
 AF Atrial fibrillation 
ASCOD Atherosclerosis, Small-vessel disease, Cardiac pathology, 
Other causes, or Dissection 
ATC Anatomic Therapeutic Chemical classification system 
CCS Causative Classification of Stroke 
CI Confidence interval 
COPD Chronic obstructive pulmonary disease 
CrCl Creatinine clearance calculated by the Cockcroft-Gault 
formula 
CYP Cytochrome P450 
HR Hazard ratio 
ICD-10 International Classification of Disease-10th Revision 
INR International normalised ratio 
LMWH Low molecular weight heparin 
NOAC Non-vitamin K antagonist oral anticoagulant 
OAC Oral anticoagulant 
OR Odds ratio 
PCI Percutaneous coronary intervention 
PT Prothrombin time  
sHR Subhazard ratio 
TIA Transient ischaemic attack 
TOAST Trial of Org 10172 in Acute Stroke Treatment 
TTR Time in therapeutic range 
VKA Vitamin K antagonist 
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1 INTRODUCTION 
 
As clinical evidence of the stroke preventive effect of oral anticoagulants (OACs) amongst 
individuals with atrial fibrillation (AF) has increased, and the cardio-oncological perspective 
has attracted more attention (not least by the foundation of the European Society of 
Cardiology Council of Cardio-Oncology in 2018), interest has been directed towards OAC 
use amongst patients with AF and concomitant cancer. Contrary to other complicating 
comorbidities such as dialysis-dependent kidney disease or previous major bleedings, nothing 
is mentioned about how to handle OAC as stroke prevention in the presence of cancer in the 
current European AF guidelines.1 The same applies to the American2 and Australian AF 
guidelines,3 which implies that treatment decisions regarding this group of patients has been 
very much left to the individual clinician. 
 
Current statistics show an ageing population and ever more cancer survivors. This is to a 
large extent an effect of modern treatments turning cancer into more of a chronic and 
manageable disease. As OAC treatment has become established through accumulated 
scientific evidence and updated AF guidelines in the general population, there is an 
increasing need for guidelines on stroke prevention in the growing population of AF patients 
with cancer. 
 
 
 
Figure 1: Illustration of the comorbidity intersect between AF, ischaemic stroke, and cancer.  
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2 BACKGROUND 
 
2.1 ATRIAL FIBRILLATION 
The electrocardiographic definition of AF is the presence of irregular R-R intervals without P 
waves, and an atrial rate of > 300 per minute for a minimum of 30 seconds. AF is considered 
to be paroxysmal if the attacks terminate within seven days, and persistent if the attacks last 
longer than seven days. Permanent AF is defined as an accepted AF where no rhythm control 
is pursued. The major risk factors for the development of AF – except ageing and genetic 
predisposition – are hypertension, coronary artery disease, obesity, heart failure, and 
diabetes.1 
AF has an overall prevalence of at least three per cent in the adult population,4,5 making it the 
most common chronic arrhythmia in patients over 65 years. AF is frequently clinically silent 
and therefore undiagnosed, as shown in screening studies.6 It has been estimated that up to 
one third of all AF is yet undiagnosed.1 As prevalence increases with age, it has been 
estimated to be about 14–24% in 80 to 85-year-olds.7,8 The prevalence of AF has doubled in 
the last decade and by the year 2060 it is expected to double once more amongst people over 
the age of 55 years in Europe.8,9  
 
 
Figure 2: Projected number of adults with AF in the European Union between 2000 and 2060. Graph 
reproduced with permission from the publisher.8 
 
AF is associated with a 1.5-fold mortality amongst men and a doubled mortality amongst 
women,10-12 as well as with increased morbidity such as heart failure and stroke.11,13,14 
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2.2 CARDIOEMBOLIC STROKE 
Ischaemic stroke, defined as an acute focal neurological symptom for more than 24 hours or 
with radiological evidence of an acute lesion in a corresponding neuroanatomical location, is 
most often caused by occlusion of a cerebral artery. In cardioembolic stroke, the occlusion is 
caused by an embolus emanating from a thrombus formed in the heart due to disturbed blood 
flow. 
There are several stroke classification systems, of which Trial of Org 10172 in Acute Stroke 
Treatment (TOAST) belongs to the most used and well-known in clinical practice. It 
identifies the following stroke etiologies: 1) large-artery atherosclerosis, 2) cardioembolism, 
3) small-artery occlusion, 4) stroke of other determined etiology, and 5) stroke of 
undetermined etiology. For the diagnosis of cardioembolic stroke, at least one cardiac source 
for an embolus must be identified.15 The stroke classification systems Causative 
Classification of Stroke (CCS)16 and Atherosclerosis, Small-vessel disease, Cardiac 
pathology, Other causes, or Dissection (ASCOD)17 acknowledge the coexistence of multiple 
stroke risk factors, thereby assigning a certain probability to all identified stroke mechanisms. 
TOAST, CCS, and ASCOD to a large extent agree on the high-risk sources of cardiac 
embolism, amongst which one of the most important is AF. 
 
Table 1 
High-risk sources of cardiac embolism according 
to the stroke classification systems TOAST, 
CCS, and ASCOD.18 
Mechanical prosthetic heart valve 
Atrial fibrillation/flutter 
Left atrial/ventricular thrombus 
Myocardial infarction within one month 
Dilated cardiomyopathy 
Infective endocarditis 
Regional akinesis of left ventricle 
Atrial myxoma 
Mitral stenosis 
Patent foramen ovale 
 
Non-valvular AF, regardless if intermittent or whether it is secondary to another disease or 
procedure, is associated with an approximately five-fold higher risk of ischaemic stroke and 
is the leading cause of cardioembolic stroke.11,13,19,20 Cardioembolic strokes constitute about 
one-third of all ischaemic strokes, are more prevalent with increasing age, cause more severe 
sequels, and have the highest recurrence rates and lowest survival rates.4,21-23  
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Figure 3: Prevalence of AF in relation to age in patients with ischaemic stroke. Graph reproduced with 
permission from the publisher.21 
 
The importance of cardioembolic stroke due to AF is illustrated by the fact that although the 
overall stroke incidence has decreased partly thanks to better treatment of atherosclerotic risk 
factors, cardioembolic strokes have increased nearly three-fold amongst patients over 80 
years in the last 25 years. Based on estimations, they may triple again by 2050.24,25  
Previous studies have shown that embolic stroke of undetermined source is often associated 
with subclinical AF, and that prolonged heart-rhythm monitoring increases chances of 
detecting AF.26,27 The hypothesis that many cryptogenic strokes are in fact cardioembolic is 
supported by a recent study using radiological characterisation of thrombi.28 This hints a risk 
of underestimating AF related strokes due to AF often being asymptomatic29. 
 
2.3 STROKE PREVENTION WITH ORAL ANTICOAGULANTS 
Even though the century old hypothesis about AF causing cardioembolic stroke has been 
modified by other contributing mechanisms,30 scientific evidence has been accumulated over 
time that treatment with OACs reduces the risk of ischaemic stroke by about 70% in patients 
with AF.31-33 However, stroke risk varies widely depending on the individual patient’s other 
stroke risk factors.13 This explains why prediction of ischaemic stroke in AF patients in order 
to identify patients at higher risk who would therefore benefit the most from OAC therapy, 
has been highlighted in AF guidelines.  
 
Estimating stroke and bleeding risk 
Several predictive models have been developed to help guide the clinical decision of starting 
OAC therapy in AF patients. The CHA2DS2-VASc stroke risk score, which is an extension of 
  5 
the previous CHADS2 score, was presented by Lip et al. in 2010, giving one point for each of 
congestive heart failure, hypertension, diabetes, vascular disease, female sex, age 65–74 years 
and two points for each of prior stroke and age ≥ 75 years. The score was created in a cohort 
of 1,084 adult patients with non-valvular AF off warfarin treatment at baseline and whose 
thromboembolic status after one year of follow-up was known. The outcome was the 
composite of thromboembolic events, defined as either ischaemic stroke, peripheral 
embolism, or pulmonary embolism. The conclusion of the original article was that the score 
has good ability in identifying patients with truly low stroke risk, thus not in the need of 
OAC.34 According to analyses of the CHA2DS2-VASc stroke risk score in Swedish hospital 
data, stroke risk ranges from 0.2% per year amongst individual with zero points, to 14.0% per 
year for those with nine points.35 The CHA2DS2-VASc stroke risk score has been externally 
validated many times36 and is now recommended by both the European and the 2019 update 
of the American AF guidelines. These guidelines recommend NOACs with warfarin as an 
alternative at a CHA2DS2-VASc score of one or higher, not counting points for female sex.
1,2  
Several bleeding prediction scores have been created in order to help identify the patients at 
highest risk of bleeding, for example the HAS-BLED score37. Compared with the 
HEMORR2HAGES
38 and the ATRIA bleeding risk39 scores, HAS-BLED has shown better 
discrimination. However, all scoring systems only have modest performance and low 
predictive properties.40,41 In line with the European AF guidelines, the European Society of 
Cardiology Working group on Cardiovascular Pharmacotherapy and the European Society of 
Cardiology Council on Stroke conclude that OAC treatment is recommended at increased 
stroke risk according to the CHA2DS2-VASc risk score and after assessment of the HAS-
BLED bleeding risk score in order to find manageable bleeding risks.1,42  
 
Net benefit of oral anticoagulants 
It is recommended that stroke prevention with OAC amongst AF patients be preceded by an 
estimation of the individual net benefit, meaning that benefit from the reduction in ischaemic 
stroke risk must exceed the harm from increased bleeding risk with OAC therapy. A large 
meta-analysis of antithrombotic treatment in AF patients concluded that the increased 
bleeding risk was lower than the stroke reduction, thus indicating net benefit of warfarin over 
both platelet inhibition and no antithrombotic treatment.31 This conclusion was confirmed by 
Friberg et al. in an observational register based study of nationwide Swedish AF data.43 
Corresponding results were later seen for the NOAC apixaban.44 The European AF guidelines 
recommend OAC in all patients with AF, except for patients with very low stroke risk,1 thus 
aligning with the concept of net benefit. Studies have shown that even in older patients with 
frequent falls, or with cognitive impairment, the stroke risk of untreated AF patients is 
estimated to exceed the bleeding risk with OAC.45,46 There are several examples of the net 
benefit of OACs amongst the elderly: In a prospective randomised open-label trial of warfarin 
versus aspirin amongst AF patients over 75 years of age, a net benefit defined as reduction of 
fatal or disabling ischaemic or haemorrhagic stroke or other arterial embolism was seen for 
warfarin over aspirin.47 Also an observational study of very elderly patients (aged ≥ 85 years) 
with AF showed a net benefit of OACs since the reduction of thromboembolic events 
outweighed the hemorrhagic risk.48  
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Vitamin K antagonist oral anticoagulants 
Warfarin, which is the only registered vitamin K antagonist (VKA) oral anticoagulant in 
Sweden, inhibits vitamin K oxide reductase and thereby the carboxylation of the vitamin K 
dependent coagulations factors II, VII, IV and X. 
 
 
Figure 4: Vitamin K-dependent coagulation factors (red) in the coagulation cascade. 
 
It is metabolised mainly by cytochrome P450 (CYP) 2C9 and is therefore not dependant on 
kidney function.49 The anticoagulation effect needs to be continuously monitored through 
blood measurements of the prothrombin time and international normalised ratio (PT-INR), 
with a preferable value between 2.0 and 3.0 and a time in therapeutic range (TTR) ideally 
over 70%, which is achieved in Sweden according to validations.50 
 
 
Figure 5: Odds ratios for ischaemic stroke and intracranial bleeding related to INR. Red arrow marks PT-INR 
2.0–3.0. Modified from Fuster et al. 2006.51 
  7 
Food and drug interactions are common and bridging with low molecular weight heparin 
(LMWH) is often used to overcome periods of low anticoagulation. The antidote three- or 
four-factor prothrombin complex concentrate acts instantly, while vitamin K takes up to four 
to six hours to reach full effect.52 
 
Non-vitamin K antagonist oral anticoagulants 
In December 2011 dabigatran was the first non-vitamin K antagonist oral anticoagulant 
(NOAC) subsidised for stroke prevention in patients with AF in Sweden. It was later 
followed by rivaroxaban in October 2012, apixaban in May 2013, and edoxaban in June 
2016. Dabigatran is a direct thrombin inhibitor, whereas apixaban, rivaroxaban and edoxaban 
are direct factor Xa inhibitors.53  
 
 
Figure 6: Targets of non-vitamin K antagonist oral anticoagulants in the coagulation cascade. Modified from 
Hoffman et al. 2017.54 
 
Since their introduction NOAC prescriptions have increased amongst AF patients, surpassing 
warfarin overall.55 Compared with warfarin, NOACs have less food interaction, a wider 
therapeutic window, and no need for the continuous monitoring of the anticoagulation effect. 
However, impaired kidney function, low body weight, and higher age are factors that should 
be taken into consideration.1 NOACs interact with glycoprotein-P and are metabolised by 
CYP 3A4, which could interfere with other drugs, including chemotherapy. Idarucizumab 
and andexanet alfa are the antidotes approved in Sweden for dabigatran and 
apixaban/edoxaban/rivaroxaban, respectively. 
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VKA vs. NOAC 
VKA and NOACs have been compared in several clinical drug trials, amongst which the 
most important are summarised in Table 2. NOACs have been shown to be at least as 
effective with less intracranial bleedings but a higher risk of gastrointestinal bleeding 
compared with warfarin at high mean TTR32,56,57 In the presence of mitral stenosis or 
mechanical prosthetic heart valve, however, VKA is considered the only safe anticoagulant.58 
 
 
Table 2 
Currently available NOACs in Sweden 
Drug Target Half-life 
(hours) 
Dosing 
frequency 
(daily) 
Renal dosing 
adjustments 
Drug interactions Reversal 
agent 
Major trial 
comparing 
drug to 
warfarin 
Dabigatran Thrombin 12–17 Twice CrCl<30 mL/min: 
contraindicated 
Proton pump 
inhibitors, antacids, 
dronedarone, P-gp-
inhibitors 
Idarucizumab RE-LY59 
Rivaroxaban Factor Xa 5–13 Once CrCl<30 mL/min: 
avoid use 
CYP3A4 inhibitors, 
P-gp-inhibitors 
Andexanet alfa ROCKET-
AF60 
Apixaban Factor Xa 9–14 Twice CrCl<25 mL/min: 
limited data 
CYP3A4 inhibitors, 
P-gp-inhibitors 
Andexanet alfa ARISTOTLE61 
Edoxaban Factor Xa 10–14 Once CrCl 15–50 
mL/min: dose 
reduction, 
CrCl<15 mL/min: 
not recommended 
CYP3A4 inhibitors, 
P-gp-inhibitors 
Andexanet alfa ENGAGE AF-
TIMI 4862 
 
 
Undertreatment 
Although the stroke preventive effect of OACs in AF patients is superior to treatment with 
platelet inhibitors or no antithrombotic treatment,44,63 several studies have indicated problems 
with OAC undertreatment in the general AF population.64-67 Also, having a cancer diagnosis 
has been shown to increase the odds of not receiving anticoagulation therapy.68  
After the 2012 update of the European AF guidelines and the introduction of NOACs, 
temporal changes have been seen. In the Stockholm region, for example, the use of OACs 
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amongst AF patients with moderate or high stroke risk increased from 54% to 82% between 
2011 and 2018.69 Reports from the nationwide Swedish stroke register, Riksstroke, regarding 
patients suffering an ischaemic stroke, shows an increase in secondary prevention in AF 
patients from 30% in 2005 to 80% in 2019.70,71 
 
2.4 CANCER 
Cancer comprises a large group of diseases characterised by uncontrolled growth and division 
of cells, and the ability to metastasise. With age, as exposure to various risk factors 
accumulate and cellular repair mechanisms become less effective, cancer risk increases.72 
 
 
Figure 7: Cancer incidence in Sweden 2014–2016.73 
 
Cancer is the second most common cause of death in Europe after cardiovascular disease. 
Europe-wide, there has been a 50% increase in cancer incidence in the last two decades, 
mainly due to an ageing population, life style factors and earlier diagnosis. However, during 
the same time period, cancer mortality increased by only 20% due to increased survival, 
which amongst other reasons, is probably an effect of improved therapy strategies. The age-
adjusted cancer survival rates in Sweden between 1980 and 2015 are illustrated in Figure 8. 
Accounting for an ageing population, age-adjusted cancer mortality is decreasing.73,74  
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Figure 8: Age-standardised cancer survival in Sweden 1980-2015.73 
 
 
2.4.1 Related conditions 
Several conditions are associated with cancer, either directly or due to diagnostic or 
therapeutic procedures. Cancer overall is associated with increased mortality, but rates differ 
between cancer types and stages, ranging from patients surviving cancer without relapses, to 
those diagnosed with an already advanced disease followed by death within a short time 
period. For several cancer types, mortality rates overlap with those of several cardiovascular 
conditions. A recent register-based study covering nearly one third of the population in the 
USA in the last four decades showed that cancer patients have on average a two- to six-times 
higher mortality due to cardiovascular disease compared to the general population. Amongst 
cancer patients, 38% died from cancer and 11% from cardiovascular disease. In cancer 
survivors diagnosed with cancer before age 55, a more than ten-times higher risk of 
cardiovascular death was seen than in the general population.75  
 
Atrial fibrillation 
Several previous studies have observed correlations between cancer and AF,76-79 and some 
have indicated higher cancer incidence after an AF diagnosis.80-82 Chances to be diagnosed 
with AF may be greater for patients with frequent hospital visits due to cancer and even 
though there is methodological heterogeneity amongst studies of AF prevalence in cancer 
patients, various mechanisms explaining this association have been presented: inflammatory 
effects on the atria,83,84 up-regulation of the sympathetic nervous system,85 and cancer 
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associated venous thromboembolism including pulmonary embolism86 inducing right heart 
strain causing tachycardia, including AF. There are several reasons other than stress and 
surgery for AF to exist amongst cancer patients, for example anti-tumoural drugs, tyrosine 
kinase inhibitors, immunotherapy, and radiotherapy, which have the capacity to cause direct 
AF inducing cardiotoxicity.87,88 
 
 
 
Figure 9: Possible causes for AF diagnosis in cancer patients. Modified from Guha et al. 2019.89 
 
Besides a higher observed prevalence of AF in cancer populations, AF has been associated 
with twice as high risk for thromboembolism, six times higher risk for heart failure,90 and 
over six times higher mortality after lung cancer surgery.91 This could also be partly an effect 
of more aggressive and potentially more AF-inducing cancer treatment in individuals with 
advanced disease92. 
 
Stroke 
Compared with the general population, cancer patients have an approximately doubled stroke 
risk,93-95 longer hospital stays and a generally worse prognosis including neurological 
impairment after a stroke.96-98 Cryptogenic stroke is about twice as common in patients with 
cancer, with an estimated proportion of 40–50%,23,99-104 which suggests the existence of 
cancer specific stroke mechanisms. It has been hypothesised that cancer induces a 
hypercoagulable state94,101,105 through multiple mechanisms. The most important among these 
include endothelial damage due to inflammation, and platelet and coagulation system 
activation. Several mechanisms associate chemotherapy to ischaemic stroke, by which 
endothelial injury, vasculitis, vasospasm, venous stasis, or general activation of the 
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coagulation cascade is induced. Radiotherapy of the head and neck region is associated with 
increased stroke risk despite no clear dose-response relationship between radiotherapy and 
carotid stenosis. Other less common cancer associated causes of ischaemic stroke are tumour 
and metastasis embolisation and direct compression of cerebral vessels.99 
 
Table 3: Cancer specific mechanisms of cerebral infarction. Modified from Neilson et al. 2018.106 
Mechanism Pathophysiology Association 
Hypercoagulability Activation of selectin and tissue factor, 
cytokine release 
Adenocarcinoma of breast, lung, 
gastrointestinal tract 
Non-bacterial thrombotic 
endocarditis 
Non-inflammatory platelet-fibrin vegetations 
on structurally normal valves in the absence 
of bacteremia 
Adenocarcinoma of breast, lung, 
gastrointestinal tract 
Radiation vasculopathy Accelerated atherosclerosis in carotid arteries, 
Moyamoya in the brain 
Head and neck tumours, acute 
lymphatic leukaemia 
Tumour embolism Direct embolisation of tumour, malignant 
cells 
Atrial myxoma, sarcoma, 
metastatic tumours to heart 
Paradoxical embolism Patent foramen ovale, right-to-left shunt All 
Chemotherapy-induced Endothelial injury, venous stasis, vasculitis, 
vasospasm, widespread activation of the 
coagulation cascade 
Cisplatin, methotrexate, L-
asparaginase, tamoxifen, 
bevacizumab 
Local tumour compression Stasis, thrombosis, spasm of cerebral 
vasculature 
Tumours metastatic to the dura, 
meningioma, pituitary adenoma 
 
 
The association between cancer and stroke is correlated to several aspects of cancer, ranging 
from stroke levels of the general population to very increased stroke risk. Analogous to 
venous thromboembolism107 certain cancer types have shown stronger association with 
ischaemic stroke than others. Some of the most common cancers, like prostate and breast 
cancers have been associated with similar or just a slightly increased stroke risk whereas 
patients with metastasised and newly diagnosed cancer have an increased stroke risk, 
compared to those without cancer.94,95,108 Particularly adenocarcinoma of the lung, pancreas, 
ovary, and colon have been linked to ischaemic stroke.93,95,99,109-111 In a large nationwide 
Swedish register based cohort study of all 820,491 patients with a cancer diagnosis between 
1987 and 2008, the overall risk – expressed as standardised incidence ratio – of ischaemic 
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stroke during the first six months after any type of cancer diagnosis was 1.6. This risk more 
than doubled for cancer of the lungs, pancreas, small intestine, endocrine glands, nervous 
system, and leukaemia compared with the non-cancer population.108 
 
Beyond various cancer specific stroke mechanisms, the classical stroke risk factors like 
hypertension, diabetes, smoking, carotid artery stenosis, and AF are considered the altogether 
most important ones, also amongst patients with cancer.99 There are some studies suggesting 
no increased risk of cardioembolic stroke amongst cancer patients.94,112 On the other hand, an 
imaging study of ischaemic stroke in patients with active cancer showed that around 67% of 
the strokes appeared as multiple embolic events, consistent with clot formation and 
embolisation,113 which anatomically shares the radiological pattern of cardioembolic stroke 
due to AF. These findings raise questions of possible underestimation of AF occurrence and 
importance. 
Studies suggesting a higher risk for ischaemic stroke amongst AF patients with cancer than 
without cancer have used imprecise definitions of active cancer, strict subgrouping, or have 
studied relatively small populations.114,115 Despite a possibly cancer-induced hypercoagulable 
state, several observational studies suggest that the attributable stroke risk from cancer is low 
compared with AF, indicating AF as the overall most important stroke risk factor.116-119 
 
Bleeding 
Several bleeding risk factors have been found in cancer patients. Even though studies differ 
with varying definitions and methods, some common factors have been identified: higher age, 
prior bleedings, anaemia, thrombocytopenia, treatment with platelet inhibitors, kidney failure, 
surgical procedures, general frailty, and cancers involving mucous membranes and 
metastases.120-123 Compared with the general population, cancer patients on OAC have 
approximately six-times higher bleeding risk,124-126 where labile TTR contributes127-130. 
Additionally, there are potential interactions between OACs and anti-tumoural treatment, as 
mentioned above (chapter 2.3). 
 
2.4.2 Atrial fibrillation and stroke prevention 
It can be clinically challenging to prescribe OAC to cancer patients because they have an 
increased risk of both ischaemic stroke and bleeding, including haemorrhagic stroke. These 
are associated with higher mortality, greater functional impairment, lower quality of life, and 
higher health and social care costs.131-133 
 
Stroke risk scores 
There have been very few validations of the recommended and established stroke risk scores 
in cancer cohorts, and the issue of the predictive ability has been discussed. A Taiwanese 
validation amongst cancer patients showed that an increasing CHADS2 stroke risk score was 
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significantly correlated with risk of thromboembolism (stroke, peripheral emboli, or 
pulmonary emboli) in patients with AF at baseline, but not in patients with new-onset AF.90 
Another validation in a cancer cohort showed that CHADS2 has a better predictive ability for 
stroke than CHA2DS2-VASc for baseline AF.
134 Yet another validation in hospitalised 
patients in Denmark with a recent cancer diagnosis showed that cancer changes the predictive 
abilities of CHA2DS2-VASc stroke risk score, implying cautious use.
114  
 
Low molecular heparin 
In the growing field of cardio-oncology, the question of AF and stroke prevention in the 
presence of cancer has raised a growing interest in the last few years. LMWH in non-
therapeutic dosage seems to be the clinician’s choice in about one third of AF patients with 
cancer according to a recent Italian single-centre study.68 A possible reason for choosing 
LMWH is that available safety data on OAC treatment in cancer patients originates from 
randomised controlled trials studying treatment of venous thromboembolism, compared with 
LMWH.135-139 Although clinicians might regard LMWH a safer alternative to OAC in cancer 
patients, bridging use of LMWH in these patients has been associated with increased bleeding 
without decreasing thrombotic risk.140 In the setting of cancer-associated venous 
thromboembolism, a meta-analysis of OACs versus LMWH shows that LMWH has better 
efficacy than VKA, but not better safety, and that LMWH and NOACs appear equal 
regarding both efficacy and safety.141 However, there is no evidence for stroke prevention 
with LMWH in AF patients,142 and it has been recommended that LMWH should be avoided 
in the acute phase after an ischaemic stroke in AF patients due to increased bleeding risk.143 
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3 AIMS 
 
The overall aim of this thesis was to increase knowledge about stroke prevention with 
OACs in the setting of AF and concomitant cancer regarding use and patient outcomes. 
 
The specific aims were: 
To assess net benefit of OAC treatment in patients with AF and cancer. 
To describe secondary prevention with OACs after ischaemic stroke amongst AF patients 
in the presence of concomitant cancer, before and after the introduction of NOACs. 
To study the influence of cancer on the benefit-risk relationship in AF patients with OAC 
treatment. 
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4 MATERIAL AND METHODS 
 
4.1 OVERVIEW OF THE STUDIES INCLUDED IN THE THESIS 
 
Study Study I Study II Study III 
Aim To estimate net cerebrovascular 
benefit of OAC treatment in 
patients with AF and cancer. 
To study secondary prevention with 
OACs after ischaemic stroke 
amongst AF patients in the 
presence of cancer, before and after 
the introduction of NOACs. 
 
To determine the influence of 
cancer on the benefit-risk 
relationship in OAC treated AF 
patients. 
Hypothesis Cancer patients with AF benefit 
from OAC treatment. 
OAC as secondary prevention after 
ischaemic stroke has increased after 
NOAC introduction, regardless of 
cancer status. 
 
Cancer does not compromise 
cerebrovascular benefit of OAC 
treatment. 
Design 
 
Cohort study Cross-sectional and cohort study Cohort study 
Data sources Patient Register, Cancer Register, 
Cause of Death Register, Drug 
Register 
 
Riksstroke, Patient Register, Cancer 
Register, Cause of Death Register, 
Drug Register 
Patient Register, Cancer 
Register, Cause of Death 
Register, Drug Register 
Study population All AF patients in Sweden All post-ischaemic stroke patients 
with AF in Sweden 
 
All OAC treated AF patients in 
Sweden 
Number of study 
participants 
Before/after propensity score 
matching: 22,596/14,472 (cancer), 
440,848/304,286 (non-cancer). 
 
1,518 (cancer), 50,953 (non-
cancer). 
8,228 (cancer), 323,394 (non-
cancer). 
Exposure 
 
OAC Cancer, NOAC introduction Cancer 
Comparison Treatment vs. no treatment Cancer vs. non-cancer, 2005–2011 
vs. 2012–2017 
 
Cancer vs. non-cancer 
Outcomes 1) Cerebrovascular benefit 
2) Composite of adverse events 
3) Bleedings 
4) Death 
 
1) OAC prescription at discharge 
2) OAC dispensation after 
discharge 
1) Cerebrovascular benefit 
2) Bleedings 
Time of data 
collection 
1 July 2005 to 31 December 2017. 1 July 2005 to 31 December 2017. 1 July 2005 to 31 December 
2017. 
Statistics Propensity score matching, 
survival analysis (Cox 
regression), competing risk 
analysis 
 
Descriptive statistics, survival 
analysis (Cox regression), cluster 
analysis, competing risk analysis 
Survival analysis (Cox 
regression), competing risk 
analysis 
Main findings 1) AF patients with cancer had a 
net cerebrovascular benefit the 
year following cancer diagnosis 
when treated with OACs. 
2) AF patients with cancer, and at 
least intermediate stroke risk, had 
a lower risk of adverse events 
including death when treated with 
OACs. 
 
1) AF patients with cancer were 
less likely to receive OAC 
treatment after ischaemic stroke. 
2) Secondary prevention has 
increased since NOAC 
introduction, but less and with 
delay amongst cancer patients. 
Amongst OAC treated AF 
patients: 
1) Net cerebrovascular benefit 
was similar for patients with and 
without cancer. 
2) Cancer was associated with 
an overall increased risk of non-
fatal bleedings. 
Publication Europace 2020. J Intern Med 2020. Submitted. 
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4.2 REGISTERS 
This thesis is based on register data of all patients with an AF diagnosis in the Swedish 
national Patient Register during the time period 1 July 2005 and 31 December 2017. Using 
the twelve-digit personal civic registration number, which is given to every permanent 
resident in Sweden upon birth or immigration for life-long use, cross-linking to other health 
registers was coordinated by the National Board of Health and Welfare. The dataset was 
anonymised according to regulations before being handed over to us for research purposes. 
The national Patient Register144 collects data on all admissions and visits at public hospitals 
and hospital-associated outpatient units in Sweden since 1987. Since 1 July 2005 all 
dispensations of prescribed medication in Sweden are registered in the Drug Register,145 
allowing cross-matching with other Swedish health registers. The Swedish Cause of Death 
Register is highly complete; all deaths reported to the tax authority since 1997 are 
included.146 The Cancer Register is prospective and collects information on diagnosed 
malignancies.147 Riksstroke,148 which is a prospective register established in 1994, collects 
information on comorbidity, therapeutic procedures, pharmacological treatment, and social 
needs and efforts in conjunction with stroke events. It was created to help develop and 
improve stroke care in Sweden at any of the 72 hospitals throughout Sweden that admit acute 
stroke cases. 
 
4.3 STUDY DESIGN AND STUDY POPULATION 
4.3.1 Definitions 
General inclusion and exclusion criteria 
All studies of this thesis were restricted to patients with AF, with either active cancer (cancer 
patients) or no cancer (non-cancer patients). Active cancer was defined by a new cancer 
diagnosis registered in the Patient Register and/or the Cancer Register within one year before 
baseline, not preceded by any cancer diagnosis up to five years before baseline. Individuals 
were, on the other hand, regarded as non-cancer patients if they had not received any cancer 
diagnosis during the five years before baseline. Basalioma was excluded from the cancer 
definition because it does not share the metastatic feature of other cancers. Patients under 18 
or over 100 years of age were excluded, as well as patients with an absolute cardiological 
indication for OACs (mitral stenosis, mechanical heart valve), or who died before start of 
follow-up. 
 
Comorbidity 
In Studies I and III, comorbidity at baseline was defined by diagnosis codes registered in the 
Patient Register back to 1997 when the International Classification of Disease-10th Revision 
(ICD-10) was implemented in Swedish health care. In Study II, additional information was 
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collected from the Riksstroke register regarding hypertension and diabetes diagnoses, as well 
as for social factors such as need for home assistance. Because the impact of alcohol use is 
difficult to measure but is still a potential confounder when studying use of OACs, we created 
a variable named alcohol-related disease. This is based on the alcohol index used by the 
Public Health Agency of Sweden and consists of diagnosis codes from the Cause of Death 
register used by the National Board of Health and Welfare to describe alcohol-related 
death.149 
 
Anticoagulants 
For the main analyses we studied OACs that are defined as either VKA (warfarin) or 
NOACs. Use was defined as at least one dispensed prescription. In Study II we additionally 
studied OAC prescription at discharge after ischaemic stroke according to the Riksstroke 
register. 
 
Risk scores 
The CHA2DS2-VASc stroke risk score
34 was defined as one point each for heart failure, 
hypertension, diabetes, vascular disease, female sex, age 65–74 years and two points each for 
prior stroke and age ≥ 75 years. In accordance with previous studies and current AF 
guidelines,1,150 the score did not include points for female sex. A CHA2DS2-VASc score of 
zero was regarded as a low stroke risk, one point was regarded as an intermediate risk, and 
two or more points were regarded as high stroke risk. 
The HAS-BLED bleeding risk score37 was defined as one point each for hypertension, 
abnormal renal/liver function, stroke, bleeding history or predisposition, age > 65 years, 
medication predisposing to bleeding, and alcohol-related disease, not accounting for labile 
PT-INR which was not available. Low bleeding risk was estimated at zero to one point, 
intermediate at two points, high at three to five points, and very high bleeding risk at more 
than five points. 
 
Diagnosis code position 
Based on a validation of diagnosis codes for bleedings in the Swedish Patient register,151 any 
diagnosis code position was accepted for bleeding outcome events. For thromboembolic 
events, including ischaemic stroke, only primary and secondary diagnosis codes were 
considered. 
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4.3.2 Study I 
Study I is a retrospective cohort study of outcome events that compares those with and 
without OAC treatment and analyses cancer and non-cancer patients separately. All 
individuals with an AF diagnosis in the Patient Register were included at the first registered 
AF diagnosis between 1 July 2005 and 1 October 2017, defining index. Baseline was defined 
as 90 days after index. This blanking period was applied in order not to miss out on OAC 
initiation after AF diagnosis as well as to avoid overestimation of event rates due to possible 
double-counting of diagnosis codes at clinic transfer after stroke. Comorbidity data was 
collected until baseline. Exposure was OAC use, defined as dispensation of OAC from four 
months before and up to baseline. The reference was not having dispensed OACs. 
 
4.3.3 Study II 
All patients discharged alive after the first registered ischaemic stroke event between 1 July 
2005 and 30 December 2017 in Riksstroke, and an AF diagnosis according to the Patient 
Register at the latest at discharge, were included. 
The first part of Study II was a cross-sectional study of OAC prescription at the time of 
discharge. The second part of Study II was a retrospective cohort study of OAC dispensation 
during follow-up. The date of discharge was defined as baseline. The exposures were cancer 
and discharge after the introduction of NOACS whereas the corresponding references were 
non-cancer and discharge before the introduction of NOACs. 
 
4.3.4 Study III 
Study III is a retrospective cohort study comparing outcome events in OAC treated AF 
patients with and without cancer. All those with an AF diagnosis between 1 January 2006 and 
31 December 2017, having dispensed at least one OAC prescription at the earliest six months 
before the AF diagnosis and at the latest 30 December 2017, were included. The first 
registered OAC dispensation was defined as baseline. Exposure was cancer while the 
reference was no cancer. 
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4.4 OUTCOMES AND FOLLOW-UP 
 
Table 4: Outcome definitions 
Variables ICD-10/procedure/ATC code beginning with 
Ischaemic stroke I63 
Extracranial arterial thromboembolism I74 
Intracranial bleeding I60, I61, I62, S064, S065, S066 
Gastrointestinal bleeding I850, I983, K226, K250, K252, K254, K256, K260, 
K262, K264, K266, K270, K272, K274, K276, 
K280, K282, K284, K286, K290, K625, K661, 
K920, K921, K922 
Bleedings (hospital treated major or non-major 
clinically relevant bleedings) 
D629, I312, M250, R040, R041, R042, R048, R049, 
R58, H313, H356, H431, R31, N421, N938, N939, 
KCV22, DR029, and codes for intracranial and 
gastrointestinal bleedings 
OAC B01AA01 (dicoumarol), B01AA03 (warfarin), 
B01AF01 (rivaroxaban), B01AF02 (apixaban), 
B01AF03 (edoxaban), B01AE07 (dabigatran) 
 
4.4.1 Study I 
The primary outcome was cerebrovascular benefit defined as reduced risk of the combined 
endpoint ischaemic stroke/intracranial bleeding. The secondary outcomes were the composite 
adverse events (consisting of ischaemic stroke, extracranial arterial thromboembolism, 
bleedings, and death) as well as bleedings and death as separate endpoints. Follow-up was 
initiated at baseline and ended by the outcome event of interest registered in the Patient 
Register, emigration, death as stated by the Cause of Death Register, or end of follow-up (31 
December 2017). 
 
4.4.2 Study II 
The primary outcome for the cross-sectional/descriptive part of the study was OAC 
prescription at discharge after ischaemic stroke. For the cohort part of the study the primary 
outcome was OAC dispensation after discharge, whereby follow-up started at discharge, and 
ended by what came first of the outcome event, emigration, death, one year since discharge, 
or study end (31 December 2017). 
 
4.4.3 Study III 
The primary outcome was cerebrovascular benefit defined as reduced risk of ischaemic stroke 
or intracranial bleeding. The secondary outcome was bleedings, defined as an admission to a 
hospital with a bleeding diagnosis. Follow-up was initiated by the first OAC dispensation 
adjacent to first AF diagnosis, and ended by either the outcome event, emigration, death, or 
end of follow-up (31 December 2017), whichever came first. 
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4.5 STATISTICAL METHODS 
4.5.1 General 
Descriptive data were presented as means or proportions. Differences between groups were 
described with standardised differences. Incidence rates were presented as events per 100 
patient-years. Tests were two-sided and used 95% confidence intervals (CIs). P-values < 0.05 
and standardised differences > 10% were considered significant. 
All analyses were performed using Stata version 15.1 (StataCorp, College Station, TX, USA). 
 
4.5.2 Study I 
Analyses were made in cancer and non-cancer patients, separately. 
A propensity score for the likelihood of OAC use at baseline was obtained by logistic 
regression including age, sex, heart failure, hypertension, diabetes, prior ischaemic stroke, 
prior transient ischaemic attack (TIA), vascular disease, prior bleeding, anaemia, recent 
venous thromboembolism, chronic obstructive pulmonary disease (COPD), dementia, 
alcohol-related disease, obesity, thyroid disease, liver disease, prior percutaneous coronary 
intervention (PCI), cardioversion, two or more falls causing hospital visits, time since first 
registered AF diagnosis, and amongst cancer patients the presence of metastases. We made a 
greedy nearest neighbour propensity score matching 1:1 without replacement, using a calliper 
width of 0.001. Multiple imputation was conducted for missing data regarding the metastasis 
variable. 
Hazard ratios (HRs) with 95% CIs were calculated for the studied outcomes using the Cox 
proportional hazards model on propensity score matched data. Fine and Gray’s proportional 
subhazards model was used to take the competing risk of death owing to other causes than the 
studied outcome event into account. This semiparametric model focuses on the cumulative 
incidences function, indicating the likelihood of the outcome event to occur before a certain 
time. 
Main analyses were conducted for the entire follow-up time. Sensitivity analyses were 
performed for a maximum follow-up time of one year, and restricted analyses were made on 
patients without a diagnosis of venous thromboembolism for six months before baseline. 
Analyses were also performed on warfarin vs. NOAC treated patients. To assess possible 
residual confounding after propensity score matching, analyses for a falsification composite 
endpoint comprising cholecystitis, acute bronchitis, herpes zoster infection, cholelithiasis, 
ankle distortion, and lumbago, which do not have a known relation to OAC use, was made. 
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4.5.3 Study II 
Associations between OAC prescription at discharge and age, sex, and non-overlapping 
covariates with a significance level of 10% in the univariate analyses were analysed with 
logistic regression and were presented as odds ratios (ORs). A recent AF diagnosis was 
defined by a first diagnosis within maximum one month before baseline. The year of 
discharge was used as an ordinal variable for the time periods 2005–2008, 2009–2011, 2012–
2014, and 2015–2017, which facilitated analyses comparing time periods before and after the 
introduction of NOACs. We categorised hospitals as community, specialised non-university, 
or university. 
The Kaplan-Meier method was used for calculating cumulative incidence of OAC 
dispensation and a Cox proportional hazards model was used for calculating HRs for first 
drug dispensation during the year following discharge. 
Adjustment for possible clustering of treatment decisions within the same hospital was made 
using generalised estimating equations with an exchangeable correlation structure for logistic 
regressions and a shared frailty model with gamma distribution using hospital as a random 
effect for the Cox regressions. For the analyses adjusting for death as a competing risk during 
follow-up, we applied the Aalen-Johansen non-parametric method for the cumulative 
dispensation and the Fine and Gray’s proportional subhazards model for the adjusted 
analyses. 
 
4.5.4 Study III 
We included heart failure, hypertension, age, diabetes, prior ischaemic 
stroke/TIA/extracranial arterial emboli, vascular disease, sex, year of OAC initation, and 
NOAC (instead of warfarin) use in all multivariable Cox proportional hazards models. For 
the analyses of the endpoint all bleedings we also included: anaemia, prior major bleeding, 
impaired kidney function, liver disease, alcohol-related disease, and frequent falls. For the 
analyses of the endpoint gastrointestinal bleedings the following were added: anaemia, prior 
major bleeding, liver disease, and alcohol-related disease. Prior intracerebral bleeding, 
impaired kidney function and frequent falls were added for the analyses of the endpoint 
intracranial bleedings. 
All analyses were adjusted for the competing risk of death due to other causes than the 
studied endpoint. We used the Aalen-Johansen non-parametric method to estimate the 
cumulative incidences of the outcome events, and the Fine and Gray’s proportional 
subhazards model for the adjusted analyses. 
 
 
 
  23 
 
4.6 ETHICAL CONSIDERATIONS 
The studies of this thesis conform to the Declaration of Helsinki, being approved by the 
regional ethics committee (EPN 2018/1252-31). Consistent with the approval, individual 
patient consent was not required or obtained. According to regulations protecting the integrity 
of the patients, an opt-out model for patient consent was used by the Riksstroke register. The 
risk of violating individual patients’ integrity within the context of these large sets of 
anonymised data generating aggregated results was very low. 
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5 RESULTS 
 
5.1 STUDY I: Net benefit of OAC treatment in AF patients with and without 
cancer 
 
Patient characteristics at baseline 
After propensity score matching on OAC treatment, patients with cancer consisted of two 
groups with 7,236 in each, with and without OAC treatment at baseline. Amongst non-cancer 
patients the corresponding matching procedure resulted in the two groups of non-cancer 
patients with 152,143 patients each, with and without OAC treatment at baseline (Figure 10). 
 
 
 
Figure 10: Selection and number of patients. Index defined as first AF diagnosis during the period 1 July 2005 
to 1 October 2017. Baseline defined as index + blanking period of 90 days. Illustration reproduced with 
permission from the publisher. 
 
Co-factors were well balanced between patients with and without OAC treatment at baseline 
in both cancer and non-cancer patients. Patients were followed for a mean of 2.4 years 
(interquartile range 0.8–5.4 years). 
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Primary outcome 
Cerebrovascular events 
Accounting for the competing risk of death, OAC treatment was associated with a risk 
reduction of 20% (subhazard ratio [sHR]: 0.80, CI: 0.78–0.81) over the entire study period in 
non-cancer patients. Amongst cancer patients, a significant association with a decrease in 
cerebrovascular events was seen when follow-up time was limited to maximum one year 
(sHR: 0.67, CI: 0.55–0.83). This applied to ischaemic stroke (sHR: 0.54, CI: 0.43–0.69) as 
well. Analyses within each cancer type subgroup showed no significant associations between 
OAC treatment and cerebrovascular events. 
 
Secondary outcomes 
Adverse events (composite of ischaemic stroke, extracranial arterial thromboembolism, 
bleedings, and death) 
OAC treatment was associated with lower risk of adverse events compared to no OAC 
treatment in both cancer patients (HR: 0.81, CI: 0.78–0.85) and non-cancer patients (HR: 
0.81, CI: 0.80–0.82). 
 
 
Figure 11: Cumulative incidence of adverse events in relation to OAC treatment amongst AF patients with 
cancer. Patients propensity score matched on OAC treatment at baseline. Graph reproduced with permission 
from the publisher. 
 
When analyses were performed for patients of various stroke risk levels, benefit from OAC 
treatment was seen for cancer patients with intermediate and high stroke risk (Table 5). 
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Table 5: Adverse events: Analyses for different stroke risk levels in AF patients with vs. without OAC 
treatment. Cancer and non-cancer patients separately propensity-score matched on OAC use at baseline. 
Significant P-values in italics. 
 CANCER 
Adverse events 
 NON-CANCER 
Adverse events 
CHA2DS2-VASc 
stroke risk level 
 HR 95% CI P-value  HR 95% CI P-value 
any no OAC reference    reference   
 with OAC 0.81 0.78–0.85 <0.001  0.81 0.80–0.82 <0.001 
low no OAC reference    reference   
 with OAC 1.25 0.82–1.91 0.307  1.13 1.05–1.21 0.001 
intermediate no OAC reference    reference   
 with OAC 0.82 0.70–0.96 0.014  1.00 0.96–1.04 0.911 
high no OAC reference    reference   
 with OAC 0.82 0.79–0.86 <0.001  0.79 0.78–0.80 <0.001 
 
Analyses within each cancer type subgroup showed that OAC treatment was associated with 
lower risk of adverse events for all cancer types, except for pancreatic, lung and prostate 
cancer, where no differences were seen. Excluding cancer patients with previous venous 
thromboembolism did not alter the association between OAC treatment and lower risk of 
adverse events (HR: 0.82, CI: 0.79–0.86). 
 
Bleedings 
After adjusting for the competing risk of death, OAC treatment was associated with higher 
risk for hospital-treated bleedings amongst cancer patients (sHR: 1.09, CI: 1.02–1.17). 
However, when limiting follow-up time to maximum one year, there was no such significant 
association (sHR: 0.93, CI: 0.84–1.03), including intracranial bleedings (sHR: 1.03, CI: 0.72–
1.46). Analyses within each cancer type subgroup showed that OAC was associated with a 
significantly higher bleeding risk only amongst patients with urological cancer. 
 
Death 
OAC treatment was associated with lower mortality amongst cancer patients (HR: 0.79, CI: 
0.76–0.82), mostly depending on clear associations seen in those with intermediate (HR: 
0.77, CI: 0.64–0-93) and high (HR: 0.79, CI: 0.75–0.82) stroke risks. The lower mortality 
remained after limiting follow-up time to maximum one year (HR: 0.68, CI: 0.64–0.73). 
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Warfarin vs NOACs 
In OAC treated cancer patients, NOACs were associated with lower risk for cerebrovascular 
events than warfarin (sHR: 0.65, CI: 0.48–0.88). This was driven by the decrease in 
ischaemic stroke events (sHR: 0.45, CI: 0.30–0.69). 
 
5.2 STUDY II: Secondary prevention with OACs after ischaemic stroke 
amongst AF patients with and without cancer, before and after the 
introduction of NOACs 
 
Patient characteristics 
At stroke onset and discharge 
From Riksstroke 52,471 patients (53.1% women) who had suffered an ischaemic stroke 
fulfilled the inclusion criteria. Amongst these, 1,518 had cancer and 50,953 had no cancer. 
Urological cancer (31.0%) and gastrointestinal cancer (27.7%) were the most common cancer 
types. At stroke onset 21.4% of the included patients used OACs. Cancer and non-cancer 
patients were alike regarding OAC use, inclusion year, need of home assistance, stroke 
severity, and hospital type. The majority of patients (46.9%) were treated at specialised non-
university hospitals. 
Cancer and non-cancer patients did not differ significantly regarding CHA2DS2-VASc scores 
(5.9 points). Compared with non-cancer patients, cancer patients had a marginally higher 
HAS-BLED score of 3.5 points (vs. 3.3 points) and more often had a previously diagnosed 
AF, venous thromboembolism, COPD, defects of function in platelets or coagulation, and 
previous gastrointestinal bleedings or anaemia. Cancer patients were less often women or 
individuals with dementia. There were no differences between cancer and non-cancer patients 
regarding discharge destination and proportion of prescribed platelet inhibitors at discharge. 
Differences in stroke and bleeding risks observed between cancer and non-cancer patients 
remained when comparing the time periods before and after NOAC introduction (Table 6). 
 
Table 6: Comparison of the time periods 2005–2011 and 2012–2017: Stroke and bleeding risk scores in 
patients with AF and ischaemic stroke, cancer vs. non-cancer patients. Standardised differences > 0.10 in 
bold. 
Risk scores at 
discharge 
2005–2011 2012–2017 
 Cancer Non-cancer Standardised 
difference 
Cancer Non-cancer Standardised 
difference 
CHA2DS2-VASc score 
(mean) 
HAS-BLED score 
(mean) 
5.8 
 
3.4 
5.8 
 
3.2 
-0.005 
 
-0.231 
6.0 
 
3.6 
5.9 
 
3.4 
-0.093 
 
-0.175 
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Comparing cancer types over time revealed an increase in the proportion of gastrointestinal 
cancers, but a decrease of urological and breast cancers (Table 7). 
 
Table 7: Comparison of the time periods 2005–2011 and 2012–2017: Cancer characteristics at the time of 
discharge after ischaemic stroke. Standardised differences > 0.10 in bold. 
Cancer patients 2005–2011 
n = 767a 
2012–2017 
n = 751b 
Standardised 
difference 
Cancer site 
   Breast 
   Gastrointestinal 
   Gynaecological 
   Haematological 
   Intracranial 
   Lung 
   Urological 
   Other 
 
10.0% 
24.5% 
5.9% 
6.4% 
0.9% 
6.8% 
34.8% 
12.9% 
 
7.1% 
30.9% 
5.2% 
8.4% 
1.3% 
9.2% 
27.0% 
12.9% 
 
0.107 
0.143 
0.029 
0.077 
0.040 
0.090 
0.169 
0.000 
Metastases* 14.3% 16.8% 0.067 
 
Note: 
a
 2.7% of study population 2005-2011. 
b
 3.1% of study population 2012–2017. *Missing data on cancer 
stage 52.8% and 34.8%, respectively. 
 
 
Primary outcome 
OAC prescription at discharge after ischaemic stroke 
Comparing the time periods before and after the introduction of NOACs, there was an 
increase in OAC prescription at discharge of 40.2% amongst cancer patients and of 69.3% 
amongst non-cancer patients (Table 8). 
 
Table 8: Proportions of AF patients discharged with OAC prescription after ischaemic stroke: cancer vs. non-
cancer. Standardised differences > 0.10 in bold. 
Time period Cancer Non-cancer Standardised 
difference 
2005–2011 32.1% 36.5% 0.094 
2012–2017 45.0% 61.8% 0.342 
 
 
As illustrated in Figure 12, the increase in OAC prescriptions at discharge was proportional to 
the increase in NOACs. 
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Figure 12: Proportion of AF patients prescribed OACs at discharge after ischaemic stroke 2005–2017. 
Graphs reproduced with permission from the publisher. 
 
Overall, OAC prescriptions at discharge were inversely related to both stroke and bleeding 
risks in cancer as well as in non-cancer patients. Differences between cancer and non-cancer 
patients were greater after the introduction of NOACs. 
Several predictors of OAC prescription at discharge were observed amongst cancer patients: 
later year of discharge, OAC use at the time of stroke onset, no previous home assistance, and 
discharge back to own home. Patients who were older, had dementia, or had had previous 
ischaemic stroke or major bleedings were less likely to be prescribed OACs at discharge. In 
relation to individuals with gastrointestinal cancer, those with lung cancer were less likely to 
be prescribed OACs, and patients with gynaecological and urological cancer had a greater 
chance of prescription. 
 
Secondary outcomes 
Dispensation of OACs after ischaemic stroke: temporal trends 
Follow-up time after the introduction of NOACs, compared with before, was associated with 
higher likelihood of OAC dispensation. However, this was more pronounced in non-cancer 
patients (HR: 2.02, CI: 1.97–2.07) than in cancer patients (HR: 1.52, CI: 1.30–1.79).  
During the time period before the introduction of NOACs, the cumulative OAC dispensation 
after one year of follow-up did not differ significantly between cancer and non-cancer 
patients. After NOACs had been introduced, however, cancer patients had dispensed less 
(estimated cumulative incidence 64.5%) than non-cancer patients (74.9%) (Table 9). 
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Table 9: Cumulative OAC dispensation during the year following ischaemic stroke in patients with AF per 
time period, cancer vs. non-cancer. P-values < 0.05 in bold 
Time period 
 
Cancer Non-cancer Log rank test 
2005-2011 43.8% (40.0–47.9%) 46.0% (45.4–46.7%) 0.073 
2012-2017 64.5% (60.2–68.8%) 74.9% (74.3–75.5%) <0.001 
 
 
The median time to dispensation/censoring was longer in cancer patients (94 days, CI: 81–
140), than in non-cancer patients (30 days, CI: 28–31) after the introduction of NOACs 
(Figure 13). 
 
 
Figure 13: Cumulative OAC dispensation during the year following ischaemic stroke in AF patients per time 
period, cancer vs. non-cancer. Graphs reproduced with permission from the publisher. 
 
Factors associated with OAC dispensation during follow-up were mostly the same as those 
seen at discharge, with a few exceptions; cancer patients with a recent AF diagnosis and those 
with a less severe stroke were more likely to be dispensed OAC (HR: 1.35, CI: 1.13-1.62 and 
HR: 1.34, CI: 1.00-1.80, respectively). Accounting for the competing risk of death during 
follow-up, previous major bleedings were negatively associated with OAC dispensation not 
only in non-cancer patients, but in cancer patients as well (sHR: 0.78, CI: 0.62–0.99). 
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5.3 STUDY III: Cancer and the benefit-risk relationship in OAC treated AF 
patients 
 
Patient characteristics 
The study population, which is described in Table 10, consisted of patients who were initiated 
on OAC adjacent to the first registered AF diagnosis during the study time. The proportions 
of men, patients with more advanced age, history of anaemia, gastrointestinal bleedings, 
venous thromboembolism, and higher stroke and bleeding risks according to the CHA2DS2-
VASc and HAS-BLED scores, were higher amongst cancer patients, compared with non-
cancer patients. NOAC use did not differ between cancer and non-cancer patients (30.4% vs. 
26.8%). Urological cancer was the most common cancer type (35.6%), followed by 
gastrointestinal cancer (19.1%), haematological cancer (10.7%), breast cancer (9.1%), lung 
cancer (6.8%), gynaecological cancer (4.9%), and brain tumours (1.3%). 
 
 
Table 10: Baseline data at OAC initiation: Variables differing significantly between cancer and non-cancer 
patients. Standardised difference > 10% in bold. 
 At OAC initiation 
 
Cancer Non-cancer Standardised 
difference 
N (%) 8,228 (2.5%) 323,394 (97.5%) 
 
Female 36.5% 43.3% 0.139 
Age (mean) 75.1 73.1 -0.211 
Year of OAC initiation 
    2005–2011 
    2012–2017 
 
46.6% 
53.4% 
 
52.8% 
47.2% 
 
0.123 
Risk scores at OAC initiation 
    CHA2DS2-VASc (mean) 
    HAS-BLED (mean) 
 
3.0 
2.3 
 
2.8 
2.0 
 
-0.129 
0.188 
Comorbidity at OAC initiation 
    Hypertension 
    Prior anemia 
    Prior gastrointestinal bleed 
    Venous thromboembolism < 6 months 
 
55.3% 
17.6% 
6.7% 
9.6% 
 
49.7% 
8.0% 
4.2% 
4.3% 
 
0.113 
0.290 
0.108 
0.211 
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Figure 14: Cumulative incidences of cerebrovascular events and bleedings during the year following OAC 
initiation in AF patients, cancer vs. non-cancer. Graphs reproduced with permission from the publisher. 
 
 
Primary outcome 
Cerebrovascular events 
Accounting for the competing risk of death during follow-up, cancer was generally not 
associated with higher risk for cerebrovascular events (sHR: 1.12, CI: 0.98–1.29); however, 
an increased risk was seen for patients with brain tumours (sHR: 3.85, CI: 2.10–7.04) and 
breast cancer (sHR: 1.52, CI: 1.04–2.22). 
Several predictors of cerebrovascular events were identified. Those with the strongest 
associations were higher age, the thromboembolism composite ischaemic 
stroke/TIA/extracranial arterial emboli, and prior intracerebral bleeding. NOAC use instead 
of warfarin use was associated with a lower risk for cerebrovascular events (sHR: 0.78, CI: 
0.73–0.83) (Table 11). 
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Table 11: Adjusted associations with cerebrovascular events accounting for the competing risk of death. 
sHR=1.00 indicates no significant association. P-values < 0.05 in bold. 
 
Multivariable sHR (95% CI) 
 
P-value 
Age ≥ 85 yearsa 2.80 (2.55–3.08) <0.001 
Prior ischaemic stroke, TIA or extracranial 
arterial embolism 
2.26 (2.15–2.37) <0.001 
Age 75–84 yearsa 2.12 (1.94–2.30) <0.001 
Prior intracerebral bleeding 2.11 (1.77–2.52) <0.001 
Age 65–74 yearsa 1.44 (1.31–1.57) <0.001 
Impaired kidney function 1.20 (1.08–1.34) 0.001 
Diabetes 1.20 (1.13–1.27) <0.001 
Hypertension 1.19 (1.13–1.26) <0.001 
Frequent falls 1.14 (1.02–1.26) 0.016 
Cancer 1.12 (0.98–1.29) 0.097 
Vascular disease 1.07 (1.02–1.14) 0.013 
Year of OAC initiationb 1.02 (1.01–1.03) <0.001 
Female sex 0.98 (0.93–1.03) 0.387 
Heart failure 0.95 (0.89–1.00) 0.057 
NOAC treatmentc 0.78 (0.73–0.83) <0.001 
aReference: Age < 65 years; bReference: 2005; cReference: Warfarin treatment. 
 
 
Secondary outcomes 
Bleedings 
During the follow-up year after OAC initiation, cancer patients had an overall 69% higher 
risk for bleedings than non-cancer patients (sHR: 1.69, CI: 1.56–1.82). Of all bleedings, 
25.8% were gastrointestinal, and 16.0% were intracranial. The risk for gastrointestinal 
bleedings was higher amongst those with gastrointestinal (sHR: 1.70, CI: 1.28–2.26), 
urological (sHR: 1.59, CI: 1.23–2.07), and haematological cancer (sHR: 1.58, CI: 1.04–2.41). 
Intracranial bleedings were associated with brain tumours (sHR: 8.59, CI: 4.12–17.90), and 
breast cancer (sHR: 2.35, CI: 1.33–4.16). No statistically significant associations were seen 
between cancer and fatal bleedings in general (sHR: 1.17, CI: 0.80–1.70) or with fatal 
intracranial bleedings (sHR: 1.13, CI: 0.71–1.82) taking the competing risk of deaths due to 
other causes into account. 
Besides cancer, some other significant predictors of bleedings were: advanced age, anaemia, 
impaired kidney function, alcohol-related disease, and prior major bleedings. NOAC instead 
of warfarin use was associated with lower risk for bleedings (sHR: 0.78, CI: 0.74–0.81). 
(Table 12) Restricting analyses to NOAC users showed no statistically significant increase 
for intracranial bleedings in the presence of cancer (sHR: 1.41, CI: 0.93–2.15). 
 
 
 34 
 
Table 12: Adjusted associations with bleedings events accounting for the competing risk of death. sHR=1.00 
indicates no significant association. P-values < 0.05 in bold. 
 
Multivariable sHR (95% CI) 
 
P-value 
Age ≥ 85 yearsa 2.80 (2.62–3.01) <0.001 
Age 75–84 yearsa 2.26 (2.13–2.41) <0.001 
Prior anaemia 1.94 (1.85–2.04) <0.001 
Cancer 1.69 (1.56–1.82) <0.001 
Impaired kidney function 1.66 (1.56–1.76) <0.001 
Age 65–74 yearsa 1.56 (1.46–1.66) <0.001 
Alcohol-related disease 1.50 (1.37–1.65) <0.001 
Prior major bleeding 1.42 (1.34–1.51) <0.001 
Liver disease 1.36 (1.19–1.54) <0.001 
Frequent falls 1.26 (1.18–1.35) <0.001 
Heart failure 1.24 (1.19–1.29) <0.001 
Vascular disease 1.20 (1.16–1.25) <0.001 
Hypertension 1.17 (1.13–1.22) <0.001 
Diabetes 1.17 (1.13–1.22) <0.001 
Prior ischaemic stroke, TIA or extracranial arterial 
embolism 
1.06 (1.02–1.10) 0.006 
Year of OAC initiationb 1.06 (1.05–1.07) <0.001 
Female sex 0.91 (0.88–0.94) <0.001 
NOAC treatmentc 0.78 (0.74–0.81) <0.001 
aReference: Age < 65 years; bReference: 2005; cReference: Warfarin treatment. 
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6 METHODOLOGICAL CONSIDERATIONS 
 
6.1 INTERNAL VALIDITY 
Two major determinants of internal validity of observational studies are study design and 
handling of systematic errors. 
 
Study design 
Interventional studies are mostly prospective and tailored to evaluate direct impacts of 
exposure on outcome. Observational studies are often retrospective and used to assess 
potential causality between exposure and outcome. The main advantages of the register-based 
cohort designs of our studies are the large amount of nationwide prospectively collected and 
complete data. Other advantages of a register-based cohort study over a classical drug trial 
are the possibilities to study prescription and drug use patterns in a real-world setting where 
follow-up time and endpoints can be flexible. Being an observational study without 
randomisation, it is only possible to report associations, not causal relationships. Studies I and 
III are about associations related to efficacy and safety, and Study II is a descriptive cross-
sectional study focussing on treatment practices. 
 
Systematic errors 
Selection bias 
Selection bias arises when the probability of inclusion is influenced by exposure (OAC use, 
introduction of NOACs, cancer) or outcome (any of the studied outcome events, including 
prescription and dispensation of OAC). Because Study I is based on all patients in Sweden 
with an AF diagnosis, this risk is minimised. The main inclusion criterion in Study II was a 
registered ischaemic stroke in the Riksstroke register, which could be influenced by 
underreporting, especially amongst patients whose prognosis is too poor to allow for 
treatment at a hospital or dedicated stroke ward. However, over the time period 2005 to 2017, 
Riksstroke was estimated to cover about 90% of all patients treated for stroke.152 In Study III, 
participation was based on being dispensed OAC, which is to some extent biased toward 
healthier individuals with better prognosis but is still representative, however, of clinical 
decisions of a real-world setting. 
A limitation of using hospital-associated health care registers is that registered diagnoses are 
conditioned on hospital contacts, thus giving selection towards heavier comorbidity and 
possible overestimation of net treatment benefit. Although these nationwide registers offer 
unique possibilities for epidemiological research, information could be scarce, especially 
amongst patients who have fewer contacts with the health care system because of social, 
economic, geographic, or psychiatric reasons. This discrepancy could lead to 
misclassification of both comorbidity and outcomes and therefore falsely assign some 
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individuals better health or lower risk. In the case of cancer patients – who are almost 
exclusively assessed at hospital facilities – we assume that this risk is low. Cancer patients 
probably have more health care contacts than non-cancer patients, and a higher probability of 
more registered diagnoses, which could lead to relative overestimating of risks. In Study II, 
we could take social factors into account to some extent by using information from 
Riksstroke on, for instance, the need of home assistance. 
The strength of all studies is that exposed and unexposed individuals were taken from the 
same data source. 
 
Information bias/Misclassification 
Information bias creates fundamental differences between groups being compared. 
Previous validations show that the Swedish National Patient Register, which collects data on 
all hospital admissions and visits at hospital-associated outpatient units, has positive 
predictive values for AF of 97%, for stroke of 88%, and for other diagnoses, amongst them 
bleedings, in the range 85–95%.153 The Cancer Register includes information on location, 
diagnostic modalities, and stage. According to a previous validation, its completeness 
regarding diagnosed malignancies is very high, even though there is some site specific 
underreporting, for example for leukaemias and lymphomas.154 In the Swedish Cause of 
Death Register, only about 0.9% of the deaths are missing an underlying cause of death due 
to underreporting, making the risk of misclassification low.146 
Because large nationwide health care registers contain mainly binary data, the risk of 
misclassification of diagnoses still constitutes a potential problem in some situations. For 
instance, in line with most other epidemiological research in this field, our studies were built 
on the assumption that the existence of an AF diagnosis indicates a cardio-embolic origin in 
the case of an ischaemic stroke. This introduces a possible risk of misclassification of stroke 
etiology, which might attenuate results. A way of increasing specificity is to use confirming 
registrations. In Study II, Riksstroke provided information about several diagnoses and drug 
use, thus backing up information retrieved from the Patient and Drug registers. On the other 
hand, double-counting of diagnosis codes at clinical transfer could overestimate outcome 
event rates, which was the reason we applied a blanking period in Study I. The risk of 
misclassification could be unevenly distributed, for example due to different reporting rates 
of stage depending on cancer type. To compensate for this, we used multiple imputation of 
cancer stage in Study I, and subgroup analyses in Study II and III. To avoid underestimating 
the outcome event of bleeding, we broadened the definition to also include in-hospital blood 
transfusions. 
Information on drug treatment has its own challenges. The chosen approach, beyond the 
complicated issues of compliance and adherence, was an intention-to-treat-like method, the 
main limitations of which are overestimation of drug use and attenuation of the drug effect. 
Warfarin is extra challenging to evaluate because estimation of actual drug effect requires 
information about PT-INR or TTR, which we did not have. Additionally, warfarin dosage 
differs greatly between individuals, making approximations of the need for a new prescription 
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at any chosen time difficult. In order to avoid data on OAC prescriptions leading to 
overestimation of actual OAC dispensation, we conducted separate analyses for these two 
entities in Study II. However, a registered dispensation could in its turn overestimate actual 
drug use, which was not possible to control for in either of the studies. Because we could not 
distinguish between therapeutic and bridging use of parenteral anticoagulants, these were 
restricted to sensitivity analyses, which did not change main results (Study I). Cancer 
treatment was estimated from dispensation of anti-tumoural drugs for self-administration, and 
procedure codes for in-hospital chemotherapy and radiation. However, cancer treatment is 
much more differentiated, and the reporting of these kind of procedures has not yet been 
validated, thus increasing the risk of misclassifying cancer severity.  
 
Confounding bias 
A confounder has associations with both exposure and outcome and is not part of the causal 
link between exposure and outcome. Randomisation – which is often used in drug trials – is 
an excellent way to distribute confounders evenly between untreated and treated individuals. 
In these observational studies, however, other methods such as restriction, stratification, 
cluster analyses, and regression analyses with adjustments were used.  
Confounding by indication is the most common limitation of observational treatment studies, 
and is present in all three studies of this thesis. We used several techniques to minimise this 
type of bias: by restricting analyses to certain subgroups in sensitivity analyses (Study I, II 
and III), to those who had recently suffered an ischaemic stroke (Study II), and to patients 
who had been initiated on OAC treatment (Study III). Additionally, we conducted propensity 
score matching155,156 on the likelihood of OAC use at baseline (Study I), adjusted for possible 
confounders (Study II and III), performed cluster analyses in order to adjust for differences in 
hospital associated treatment practices (Study II), and stratified on stroke risk (Study I), 
cancer status (Study I and III), and cancer type (Study I and III). Our analyses showed a 
nearly doubled mortality in cancer patients. When individuals who are censored do not have 
the same future risk of an event of interest due to a competing risk such as death, competing 
risk analysis methods are available. These were used throughout all studies. 
The dynamic properties of follow-up time could also increase the risk of confounding bias. A 
limitation of Study I is the change of treatment practices following revised guideline 
recommendations regarding both stroke prevention and cancer care during follow-up time. In 
Study II, which studied the introduction of NOACs, we therefore used time as an exposure 
variable. In Study III, analyses were adjusted for year of OAC initiation. The potential 
problem of treatment cross-over during follow-up and the assumed variety in development of 
cancer disease was reduced by limiting the follow-up time in the subanalyses of Study I and 
the main analyses of Studies II and III. 
Residual or hidden confounding is the systematic difference between exposed and unexposed 
patients remaining, despite the use of various statistical methods. This can occur in the 
presence of medical conditions that are difficult to characterise, registered as binary variables 
even though they are continuous, or that should ideally be measured more than once, for 
example comorbidity at baseline. One way to check for possible residual confounding after 
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propensity score matching is the use of falsification endpoints (Study I). The lack of 
association between OAC treatment and the falsification endpoint suggests that hidden 
confounding did not affect the results to any great extent.  
 
6.2 EXTERNAL VALIDITY 
The studies of this thesis are based on health care registers of prospectively recorded data 
covering the entire public hospital-associated health care system in Sweden. This is beneficial 
for the external validity, often referred to as generalisability, not only amongst hospital 
treated patients in Sweden, but probably also for other countries with similar patient 
compositions and health care systems. What could influence the generalisability negatively is 
that private health care and primary health care was not covered by the registers, even though 
the number of cancer patients missed is assumed to be negligible. Another strength is that the 
use of health registers includes patients who would most likely be ineligible for clinical trials. 
Amongst these are elderly patients with heavier comorbidity and perhaps varying attitudes 
towards treatment and participation in drug trials. 
Restricting cancer patients to those with a new diagnosis within one year before baseline was 
an attempt to somewhat standardise the situation in which clinical decisions on OAC 
treatment are often made. This increases the generalisability regarding patients with a newly 
diagnosed and therefore active cancer. However, generalisability regarding patients with a 
longer history of cancer, including both relapses and remissions, must be cautiously 
interpreted. 
 
6.3 RANDOM ERROR AND PRECISION 
The presence of random errors influence study precision. It is evaluated by the significance 
level of the statistical analyses that are conducted; this was set to 5% in conformity with most 
medical studies. 
Precision of cohort studies can suffer from small sample sizes and few outcome events. 
Despite having data covering practically all existing AF patients in Sweden back to 2005, 
stratifying the cancer group into cancer subtypes generated even smaller groups, thus 
increasing the risk for type II errors and therefore the risk of not being able to detect possible 
differences related to OAC treatment. Because the studies were based on the whole existing 
population, there was no possibility to further expand the data. Interestingly, we found 
examples that revealed subgroup size did not seem to always matter when finding statistically 
significant differences. For instance, the increased risk of intracranial bleedings amongst the 
smallest subgroup of AF patients (brain tumours) (Study III). 
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7 DISCUSSION 
 
7.1 WHY STUDY OACs IN AF PATIENTS WITH CANCER? 
As the ageing population grows, the incidences of both AF and cancer will increase. This 
highlights the importance of studying the overlap between these two common medical 
conditions. Several previous studies – which could be criticised for methodological 
heterogeneity – have not been able to show a generally increased stroke risk amongst AF 
patients with cancer versus those without cancer, implicating that AF seems to be the 
clinically most important stroke risk factor regardless of cancer status.116-119 
OAC treatment of AF patients with concomitant cancer means balancing several kinds of 
risk. Not only do cancer patients have an increased risk of venous thromboembolism and a 
higher risk of stroke but also an increased risk of bleeding, including severe bleedings. Until 
now, no randomised controlled drug trials have been conducted focussing on OAC treatment 
in AF patients with cancer. This is reflected by the absence of evidence-based guidelines 
available. Instead, consensus-based recommendations have been published, revealing the 
need for further research. Although observational studies show associations and not causality, 
they are valuable sources of information for clinical decision making which is the scope of 
this thesis. To our knowledge no practice study on secondary stroke prevention amongst AF 
patients with cancer has been conducted before. 
 
7.2 WHO GETS TREATMENT? 
By looking at the descriptive parts of Studies I and II, it is possible to investigate several 
aspects of who gets OAC treatment and who does not. We found that OAC use amongst AF 
patients was generally low. Over the entire study period, less than half of the AF patients – 
among which the majority at elevated stroke risk – were treated. The proportion was even 
lower amongst patients with cancer (Study I). In patients at the very highest stroke risk (after 
having suffered an ischaemic stroke), cancer patients were less likely to be treated with OAC 
despite known AF and a cardiovascular risk profile similar to that of patients without cancer 
(Study II). This corresponds to previous studies showing lower OAC use in AF patients with 
increased stroke risk, particularly in the presence of cancer.21,68  
 
Factors influencing treatment 
Several factors reflecting both frailty at stroke onset and worse stroke outcome were 
negatively associated with OAC treatment after ischaemic stroke. This was seen also for lung 
cancer, possibly explained by an often aggressive nature. Overestimation of the excess 
bleeding risk may be one of the most important reasons why AF patients with cancer are less 
often treated with OACs. Other factors such as short life expectancy or multifactorial 
contraindication – for which there are no specific diagnosis codes – could, however, certainly 
play a role, even though the use of falsification endpoints in Study I suggests low residual 
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confounding. Another explanation could be the overlap between stroke and bleeding risk 
factors. However, differences in OAC at discharge between cancer and non-cancer patients 
generally decreased as bleeding risk increased (Study II). The use of platelet inhibitors 
instead of OACs for patients at intermediate stroke risk – part of the European AF guidelines 
until 2010 – could also contribute, especially amongst elderly patients. 
 
Delayed treatment 
We found that the proportion of AF patients that dispensed OACs during the year following 
an ischaemic stroke was higher than the proportion discharged with an OAC prescription. 
Rates of dispensation were, however, higher in patients without cancer, indicating 
postponement of the treatment decision in cancer patients. This is further illustrated by the 
observation that a recently diagnosed AF amongst cancer patients showed no significant 
association with OAC prescriptions at discharge after ischaemic stroke but was positively 
associated with dispensation during follow-up. The delayed implementation of secondary 
stroke prevention with OACs could depend on uncertainty regarding prognosis and further 
diagnostic or therapeutic procedures during earlier phases of cancer. 
 
The introduction of NOACs 
Previous studies of general AF populations have shown that OAC use has increased 
substantially since NOACs were introduced.157-159 In Study II, we found that the introduction 
of NOACs was associated with increased OAC treatment amongst AF patients with cancer, 
driven by the share of NOACs. The increase was seen both at discharge and during follow-up 
after ischaemic stroke. Rates of dispensation were, however, higher in non-cancer patients 
and the difference was even greater after NOACs were introduced. This increase in OACs 
amongst potentially frail patients is consistent with other large register-based studies from 
Denmark and Norway that have shown increased OAC treatment in elderly patients since 
NOACs were introduced.160,161 Although the introduction of NOACs coincided with major 
updates of AF guidelines lowering the threshold of treatment, the proportion of cancer 
patients discharged with any OAC increased by 40.2%, compared to 69.3% in non-cancer 
patients, despite no change in the differences in stroke and bleeding risk between cancer and 
non-cancer patients over the study time. Thus, cancer patients did not seem to benefit from 
the faster treatment decisions that non-cancer patients benefitted from as a result of NOACs. 
This is problematic considering that AF is an established predictor of early stroke 
recurrence162 and that early NOAC initiation post-stroke has a net benefit in the general AF 
population.163 
Our interpretation is that the lack of evidence-based guidelines regarding AF patients with 
cancer challenges and therefore undermines clinical decision making. 
 
  41 
7.3 THE CONCEPT OF NET BENEFIT OR HOW TO BALANCE EFFICACY AND 
HARM 
An informed medical decision regarding treatment implies weighing potential benefits versus 
potential harms. However, there is no consensus on how to incorporate these in a single 
summary statistic. We chose to use a composite of negative events regardless of 
thromboembolism or bleedings, thus combining estimations of efficacy and safety. This 
approach may be criticised due to the difficulty of estimating to what extent a major bleeding 
endpoint causes more suffering than a thromboembolic event, or the other way around. 
Previous studies have used different ways to compare the severity of different types of 
outcomes of a treatment, for example by applying weights depending on how strong the 
association is between the outcome and death,48,164 or by arbitrarily giving a 1.5 times higher 
weight for intracranial bleeding events than for thromboembolic events.43,165,166 From a 
clinical point of view, however, it is difficult to categorically imply that bleedings would 
always override thromboembolic events, especially as register data are often binary. This is a 
reason why adding quality-adjusted life years to the endpoint has been proposed.167 Other 
studies have used multiple models, including the skipping of weights in order to avoid the 
risk of biasing,168,169 The complexity of this matter, including the lack of assigning weights 
and values to benefits and risks has also been highlighted in structured comparisons and 
evaluations of how the European Medicines Agency and the US Food and Drug 
Administration communicate benefit-risk decisions regarding new treatments.170 
In summary, there is no standard procedure to merge benefit and potential harm of treatment 
in scientific studies, which highlights the possibly even more complex situation faced by 
clinicians world-wide. Our choice to equate all hospital treated thromboembolic and bleeding 
events, minimises risks of arbitrary biasing. The risk of underestimating the impact of 
bleeding is probably compensated by our relatively broad definition of bleedings.  
 
7.4 OACs AND NET BENEFIT 
7.4.1 Cancer 
In Study III, the possible impact of OAC treatment in regard to cancer was explored. We 
found that after adjustment for comorbidity and for the competing risk of death, the net 
cerebrovascular benefit was similar in patients with and without cancer. In addition, cancer 
contributed to an overall increased risk of bleedings. These findings are in consonance with 
the post-hoc analyses of the ENGAGE AF-TIMI 48 trial on OAC treated patients with AF in 
which cancer was not associated with all-cause stroke, but with major bleedings.171 A post-
hoc analysis of the ROCKET AF trial showed similar results, but the bleeding risk of cancer 
patients was not significant for the specific endpoints ‘increased bleedings in critical organs’, 
and ‘bleedings requiring blood transfusions’.172 This differs from our results, but could 
depend on the relatively low number of outcome events, the exclusion of patients with a life 
expectancy under two years, and a less precise definition of cancer than we used. 
The post-hoc analyses of the ARISTOTLE trial showed no significant associations between 
cancer and ischaemic stroke or bleedings in OAC treated but comprised 157 patients with 
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active cancer, challenging the statistical power.173 Similar conclusions were reported in an 
observational Danish study but the lack of distinction between previous and present cancer 
could influence these results.117 On the other hand, an observational study from Italy on 
NOAC treated AF patients found elevated risk of both ischaemic stroke and bleedings in the 
presence of cancer. This study was, however, limited by a rather small cancer group, of which 
only 104 patients had active cancer.115 
 
7.4.2 Cancer type 
The issue of possibly different benefit related to cancer types was addressed in the net benefit 
analyses for different cancer types in both Study I and III. In Study I significant associations 
were seen mainly in large cancer subgroups, which raises the possibility of type II errors due 
to low sample sizes. In Study III, however, a significantly stronger association was detected 
between the smallest group of patients with brain tumours and the higher risk for 
cerebrovascular events due to higher risk for intracranial bleedings, compared with non-
cancer patients. This was also seen for patients with breast cancer, which may be explained in 
part by increased bleeding risk as a consequence of interaction between warfarin and 
selective oestrogen receptor modulators used to inhibit tumour growth.174 Previous studies 
have shown no increased OAC associated bleeding risk in AF patients with breast cancer 
compared with AF patients without cancer.117,175 In contrast to these studies, Study III had a 
stricter definition of cancer and recorded more events. 
Amongst OAC treated AF patients, those with gastrointestinal, urological, and 
haematological cancers had an increased risk for gastrointestinal bleedings. This is partly in 
line with previous studies showing a higher risk for gastrointestinal bleedings when treated 
with anticoagulants, mostly due to local barrier disruptions of the gastrointestinal tract, 
thrombocytopenia, and invasive procedures or treatments.124,176,177 
 
7.4.3 Time since cancer diagnosis 
Cancer is a dynamic condition influenced by both diagnostic and therapeutic measures as 
well as by the cancer itself. Stroke incidence has been seen to be at the highest during the first 
year after cancer diagnosis.108,111,178 Therefore, time has the potential to be of importance, 
especially regarding prognosis. To reduce the possible effect of diverging cancer severity 
over time in Study I, we additionally limited follow-up time for some analyses, revealing a 
net cerebrovascular benefit of OAC treatment during the first year following a cancer 
diagnosis in AF patients. 
 
7.4.4 Stroke risk 
There is conflicting data regarding the usefulness of stroke risk scores in cancer patients. For 
example, it has been suggested that risk scoring works more accurately in patients who 
already have AF at the time of cancer diagnosis, compared with later AF diagnosis.90 
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According to a previous study, the stroke risk score CHADS2 was found to be more useful 
than the CHA2DS2-VASc score in AF patients with cancer
134 whereas another study has 
concluded that the CHA2DS2-VASc score predicts differently depending on the presence of 
cancer.114 Our findings among AF patients with cancer in Study I, however, matched 
clinically reasonable expectations by suggesting net benefit of OAC treatment for the 
composite adverse events at elevated stroke risk according to CHA2DS2-VASc. 
 
7.4.5 Warfarin vs. NOACs 
The question of which kind of OAC to consider in cancer patients – in whom treatment 
effects are hard to predict – is of great interest. Warfarin can be closely monitored with PT-
INR whereas the effect of NOACs can be evaluated only indirectly. Nowadays there are 
reversing agents against all OACs available.  
Our analyses propose a lower risk of ischaemic stroke and a net cerebrovascular benefit with 
NOACs compared to warfarin amongst AF patients with cancer (Study I). Furthermore, AF 
patients with cancer using NOACs instead of warfarin seem to have a lower risk for 
bleedings in general and similar risk of intracranial bleeding as non-cancer patients with the 
same treatment (Study III). This is in accordance with the main findings of a recent study-
level meta-analysis of AF patients with cancer, in which at least the same efficacy of 
thromboembolic stroke prevention and less bleeding complications was shown for NOACs 
compared with warfarin.179 This corroborates drug trials in the general AF population. 
 
7.5 HOW SHOULD WE TREAT? 
7.5.1 What do current recommendations say? 
Current recommendations regarding stroke prevention in AF patients with cancer are based 
on consensus. The 2018 European Heart Rhythm Association Practical Guide on the use of 
NOACs in patients with AF recommends clinicians to look at cancer as a factor to regularly 
evaluate because of its potential to cause changes in kidney or liver function as well as 
possible drug-drug interactions with chemotherapy.142 This resembles the way the European 
AF guidelines suggest the handling of bleeding risk in the setting of OAC treatment; it is 
emphasised that an increased bleeding risk score should not automatically result in 
withholding OAC. Instead, manageable bleeding risk factors should be corrected,1 which is 
also stated in the guidelines of the International Society on Thrombosis and Haemostasis.180 
Bleeding data based on cancer patients with venous thromboembolism suggest that NOACs 
should be used with caution when the patient is affected by luminal gastrointestinal cancers 
or mucosal abnormalities such as esophagitis, gastritis, duodenal ulcers, or colitis.181 
To date there is no specific guidance about OACs as secondary prevention after ischaemic 
stroke for AF patients with cancer.  
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Anti-tumoural treatment 
It is estimated that about one third of patients with cancer receive chemotherapy.182 Tyrosine 
kinase inhibitors and monoclonal antibodies can cause bleedings due to 
thrombocytopenia.183,184 Most chemotherapy substances are not strong inducers or inhibitors 
of CYP 3A4 or glycoprotein-P, but in such case, apixaban and rivaroxaban should be used 
with caution.180 Previous trials on cancer-related venous thromboembolism that tested 
NOACs against LMWH in patients with a large proportion on chemotherapy have mostly 
shown non-inferiority regarding incidence of major bleeding. This indicates that NOACs 
seem to be safe in this particular setting.135-138  
According to a guidance on chemotherapy and OAC treatment by the Scientific and 
Standardization Committee of the International Society on Thrombosis and Haemostasis, it is 
recommended to base decisions on the comparison of possible negative effects of abstaining 
from either OAC treatment or the anti-tumoural treatment, because it could sometimes be 
preferable to anticoagulate. It is further stated, that it is also of great importance to take the 
dynamic characteristics of cancer and its treatment into consideration.180  
 
7.5.2 Implications: Practical comments regarding treatment 
Awaiting randomised controlled trials with specific focus on AF patients with cancer to 
guide clinical practice, the findings of this thesis could be combined with the suggestions 
presented in the guidance from the Scientific and Standardization Committee of the 
International Society on Thrombosis and Haemostasis180 and from the 2018 European Heart 
Rhythm Association Practical Guide on the use of NOACs in patients with AF142, as 
follows:  
-The net benefit of OAC treatment amongst AF patients with cancer and at least 
intermediate stroke risk should routinely be taken into consideration according to current 
guidelines for the general AF population, including the identification of possible 
manageable bleeding risk factors. 
-Amongst AF patients who have had an ischaemic stroke and therefore are at highest stroke 
risk, awareness of the risk for perfunctory delay of OAC treatment is warranted. 
-It is reasonable to continue the current OAC if already prescribed and well managed, while 
NOACs would be the choice when starting OAC treatment and no drug interactions are 
expected or gastrointestinal bleeding of concern. 
-NOACs seem to be a safe alternative to warfarin, but apixaban and rivaroxaban should be 
used with caution together with anti-tumoural treatments inhibiting or inducing CYP 3A4 
or glycoprotein-P. 
-Special caution is advised when the patient is affected by luminal gastrointestinal cancer or 
mucosal pathologies such as oesophagitis, gastritis, duodenal ulcers, or colitis. Prevention of 
upper gastrointestinal bleedings with proton-pump inhibitors should be considered. 
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-The dynamic nature of cancer and changes in kidney and liver function should be accounted 
for, as well as drug interactions, possible need for surgical interventions, prognosis, and 
patient preferences. 
-In addition to clinical assessments, laboratory work-up regarding signs of drug 
accumulation and bleeding should be performed regularly after OAC initiation. Extra care 
should be exercised amongst patients with brain tumours and breast cancer. 
-There is no scientific evidence for the use of LMWH as stroke prevention in AF patients 
with cancer, and safety does not seem higher than that for warfarin. In case of problems with 
oral intake, however, LMWH could be a time limited treatment option. 
-Decisions on stroke prevention with OAC in AF patients should be multi-disciplinary, taking 
cardiovascular and oncological aspects, as well as prognosis and the patient’s preferences into 
consideration. Regular assessments of the general clinical state should be done, anticipating 
preparedness to discontinue OAC treatment in terminal patients. 
 
7.6 FUTURE PERSPECTIVES 
As the population ages, the cancer incidence increases and cancer survival improves, we will 
see increasing numbers of people living with both cancer and AF. AF patients with cancer are 
an important group which needs to be further monitored regarding treatment practices 
through longitudinal studies, as awareness increases and possibly updated guidelines are 
implemented. Because present knowledge on warfarin versus NOACs amongst cancer 
patients comes from retrospective studies and post-hoc analyses of drug trials in general AF 
populations117,171-173,185,186 (summarised in the previously cited meta-analysis by Cavallari et 
al.179), there is a need for randomised drug trials of well-defined cancer populations regarding 
type and stage, as well as of different OACs. Additionally, validations of stroke and bleeding 
risk scores in well-defined cancer cohorts would also be of great utility for further assistance 
when making clinical decisions. The HEMORR2HAGES score,
38 which was created as a 
combination of three previous risk scores and the only bleeding risk score containing a 
malignancy variable,187 is an example of a clinical tool that may need further validation.  
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8 CONCLUSIONS 
 
The results support that: 1) AF patients with cancer and elevated stroke risk benefit overall 
from treatment with OACs, NOACs in particular; 2) there is probably underutilisation of 
OACs as secondary stroke prevention amongst AF patients with cancer, despite increased 
OAC use since NOACs were introduced; and 3) cancer generally does not change net 
cerebrovascular benefit of OACs, NOACs in particular, amongst AF patients, despite the 
overall increased risk of bleedings.  
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9 SVENSK SAMMANFATTNING 
 
Bakgrund 
Individer med cancer har högre risk för såväl stroke som blödning jämfört med individer utan 
cancer. Trots att befolkningen blir allt äldre och gruppen patienter som har både 
förmaksflimmer och cancer blir större, saknas riktlinjer avseende strokeförebyggande 
behandling för dessa patienter. Syftet med den här avhandlingen var att beskriva 
strokeförebyggande behandling med perorala antikoagulantia hos förmaksflimmerpatienter 
med cancer, därtill att uppskatta nettonyttan. 
 
Metod och resultat 
Registerdata avseende alla patienter med minst en registrerad förmaksflimmerdiagnos i det 
svenska patientregistret mellan 1 juli 2005 och 31 december 2017 samkördes med 
läkemedelsregistret, cancerregistret, dödsorsaksregistret och Riksstroke. Patienter med en ny 
cancerdiagnos senaste året och patienter utan cancerdiagnos senaste fem åren inkluderades. 
 
Studie I: Vi använde propensity score matchning avseende sannolikheten att behandlas med 
perorala antikoagulantia efter en förmaksflimmerdiagnos för att studera patienter med och 
utan antikoagulantiabehandling. Patienter med (n=14 472) och utan cancer (n=304 286) 
analyserades separat. Bland dem med cancer sågs nettonytta av perorala antikoagulantia 
avseende det kombinerade utfallet ischemisk stroke, extrakraniell arteriell tromboembolism, 
blödningar och död (HR: 0,81; CI: 0,78–0,85). Nettonyttan drevs av patienter med 
intermediär och hög strokerisk. När uppföljningstiden begränsades till ett år och död som 
konkurrerande utfall togs med i analysen, sågs nettonytta också avseende cerebrovaskulära 
händelser för behandling med perorala antikoagulantia generellt (sHR: 0,67; CI: 0,55–0,83) 
liksom för perorala antikoagulantia av icke vitamin K-antagonisttyp specifikt (sHR: 0,65; CI: 
0,48–0,88), jämfört med warfarin. 
Studie II: I Riksstroke identifierades alla förmaksflimmerpatienter som drabbats av en 
ischemisk stroke. Bland dem med cancer (n=1518) ökade andelen som skrevs ut med 
perorala antikoagulantia med 40,2% efter att perorala antikoagulantia av icke vitamin K-
antagonisttyp introducerats, jämfört med 69,3% bland dem utan cancer (n=50 953), detta trots 
att stroke- och blödningsriskerna förblev liknande mellan grupperna över tid. Uttag av 
perorala antikoagulantia under året som följde på en ischemisk stroke ökade mindre bland 
dem med cancer (från 43,8% till 64,5%) än bland dem utan cancer (46,0%–74,9%). 
Mediantiden till uttag var signifikant längre hos dem med cancer (94 jämfört med 30 dagar) 
efter att perorala antikoagulantia av icke vitamin K-antagonisttyp introducerats. 
Studie III: Den cerebrovaskulära nettonyttan skiljde sig inte mellan cancer- (n=8228) och 
icke-cancerpatienter (n=323 394) under året efter insättning av perorala antikoagulantia i 
anslutning till förmaksflimmerdiagnos, inberäknat död som konkurrerande risk (sHR: 1,12; 
CI: 0,98–1,29). Individer med cancer hade högre risk för icke-dödliga blödningar (sHR: 1,69; 
CI: 1,56–1,82). Perorala antikoagulantia av icke vitamin K-antagonisttyp var associerade med 
lägre risk för både cerebrovaskulära händelser och blödningar i jämförelse med warfarin. 
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Bland dem som behandlades med perorala antikoagulantia av icke vitamin K-antagonisttyp 
var cancer inte associerad till intrakraniell blödning. 
 
Slutsatser 
Förmaksflimmerpatienter med cancer har nettonytta av behandling med perorala 
antikoagulantia enligt allmänna förmaksflimmerriktlinjer, men de bör övervakas noga 
avseende blödningar. Perorala antikoagulantia av icke vitamin K-antagonisttyp ter sig säkrare 
än warfarin, men verkar underutnyttjade som sekundär strokeprevention bland patienter med 
cancer. 
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